Nothing Special   »   [go: up one dir, main page]
Wikipedia

Oliceridine: Difference between revisions

Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
→top: improve wording
Altered pages. Added url. Formatted dashes. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.
 
(34 intermediate revisions by 20 users not shown)
Line 1:
{{Short description|Opioid analgesic drug}}
{{cs1 config|name-list-style=vanc}}
{{Infobox drug
| drug_name =
| INN =
| type = <!-- empty -->
| image = TRV130.svg
| width = 250px
| alt =
| caption = <!-- Clinical data -->
| pronounce = OH li SER i deen
 
| tradename = Olinvyk
<!-- Clinical data -->
| Drugs.com = {{drugs.com|ppa|oliceridine}}
| pronounce =
| MedlinePlus =
| tradename = Olinvyk
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| Drugs.com =
| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
| MedlinePlus =
| DailyMedID = Oliceridine
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EUlicence_US = <!-- EMAFDA usesmay INNuse generic (or specialbrand name (generic name INN_EMApreferred) -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| DailyMedID = Oliceridine
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_category =
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_US_comment =
| pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration = [[Intravenous therapy|Intravenous]]<ref>{{cite web | title=Olinvyk- oliceridine injection, solution | website=DailyMed | date=18 August 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce167984-8b9d-40b7-84ce-d0f33fff1eaa#LINK_5124ccc6-4102-466b-ad71-15d663677a4a | access-date=16 September 2020}}</ref>
| routes_of_administration = [[Intravenous therapy|Intravenous]]
| class =
| ATCvet =
| ATC_prefix = noneN02
| ATC_suffix = AX07
| ATC_supplemental = <!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = Schedule II
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = <!-- For countries not listed above -->
 
<!-- Pharmacokinetic data -->| bioavailability =
<!-- Legal status -->
| protein_bound =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_commentmetabolism =
| metabolites =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_commentonset =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="FDA PR" />
| legal_EU =
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = <!-- For countries not listed above -->
 
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| >
| elimination_half-life =
| duration_of_action =
| excretion = <!-- Identifiers -->
| CAS_number_Ref =
| CAS_number = 1401028-24-7
| CAS_supplemental =
| PubChem = 66553195
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank = DB14881
| ChemSpiderID_Ref =
| ChemSpiderID = 30841043
| UNII_Ref =
| UNII = MCN858TCP0
| KEGG_Ref =
| KEGG = D11214
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL = 2443262
| NIAID_ChemDB =
| PDB_ligand = WH2
| synonyms = TRV-130, TRV130
 
<!-- Chemical and physical data -->| IUPAC_name = ''N''-[(3-Methoxythiophen-2-yl)methyl]-2-[(9''R'')-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine
<!-- Identifiers -->
| C = 22
| CAS_number_Ref =
| H = 30
| CAS_number = 1401028-24-7
| CAS_supplementalN = 2
| O = 2
| PubChem = 66553195
| IUPHAR_ligandS = 1
| SMILES = COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4
| DrugBank_Ref =
| StdInChI = 1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1
| DrugBank = DB14881
| ChemSpiderID_RefStdInChI_comment =
| StdInChIKey = DMNOVGJWPASQDL-OAQYLSRUSA-N
| ChemSpiderID = 30841043
| UNII_Refdensity =
| density_notes =
| UNII = MCN858TCP0
| KEGG_Refmelting_point =
| melting_high =
| KEGG = D11214
| ChEBI_Refmelting_notes =
| ChEBIboiling_point =
| ChEMBL_Refboiling_notes =
| solubility =
| ChEMBL = 2443262
| NIAID_ChemDBsol_units =
| PDB_ligandspecific_rotation =
| synonyms = TRV-130
 
<!-- Chemical and physical data -->
| IUPAC_name = ''N''-[(3-Methoxythiophen-2-yl)methyl]-2-[(9''R'')-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine
| C=22 | H=30 | N=2 | O=2 | S=1
| SMILES = COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4
| StdInChI = 1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1
| StdInChI_comment =
| StdInChIKey = DMNOVGJWPASQDL-OAQYLSRUSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
 
'''Oliceridine''', sold under the brand name '''Olinvyk''', is an [[opioid]] medication that is used for the treatment of moderate to severe acute [[pain]] in adults.<ref name="FDA PR">{{cite press release | title=FDA Approves New Opioid for Intravenous Use in Hospitals, Other Controlled Clinical Settings | website=U.S. [[Food and Drug Administration]] (FDA) | date=7 August 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings | access-date=7 August 2020}} {{PD-notice}}</ref> It is given by [[intravenous therapy|intravenous]] (IV) injection.<ref name="FDA PR" />
 
The most common side effects include nausea, vomiting, dizziness, headache, constipation, itchy skin and low oxygen levels in blood.<ref name="FDA snapshot" />
 
It was approved for medical use in the United States in August 2020.<ref name="FDA snapshot">{{cite web | title=Drug Trials Snapshots: Olinvyk | website=U.S. [[Food and Drug Administration]] (FDA) | date=7 August 2020 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-olinvyk | access-date=16 September 2020}} {{PD-notice}}</ref>
 
== Medical uses ==
Oliceridine is [[Indication (medicine)|indicated]] for short-term intravenous use in hospitals or other controlled clinical settings, such as during inpatient and outpatient procedures.<ref name="FDA PR" /> It is not indicated for at-home use.<ref name="FDA PR" />
 
== Adverse effects ==
Line 119:
 
=== Pharmacodynamics===
Oliceridine is a [[mu-opioid receptor|μ-opioid receptor]] [[biased agonist]] developed by [[Trevena Inc|Trevena]]. In cell-based (''in vitro'') research, oliceridine elicits robust [[G protein]] [[signal transduction|signaling]], with [[potency (pharmacology)|potency]] and [[intrinsic activity|efficacy]] similar to that of [[morphine]], but with less [[arrestin beta 2|β-arrestin 2]] recruitment and [[receptor internalization]] .<ref name="pmid23300227">{{cite journal |date vauthors =March 2013DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD | display-authors = 6 | title = A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine | journal =[[J. Pharmacol.The Exp. Ther.|Journal of Pharmacology and Experimental Therapeutics]] | volume = 344 | issue = 3 | pages =708–17|doi=10.1124/jpet.112.201616|pmid=23300227|vauthors=DeWire SM,708–717 Yamashita| DS,date Rominger= DH,March Liu2013 G,| Cowanpmid CL,= Graczyk23300227 TM,| Chendoi XT,= Pitis10.1124/jpet.112.201616 PM,| Gotchevs2cid D,= Yuan8785003 C, Koblish M, Lark MW, Violin JD|s2cid=8785003}}</ref>. However,It recenthas reportsbeen highlightsuggested that this might be due to its low intrinsic efficacy ,<ref>{{cite journal |last1 vauthors = Gillis |first1=A, |last2=Gondin |first2=AB, |last3=Kliewer |first3=A, |last4=Sanchez |first4=J, |last5=Lim |first5=HD, |last6=Alamein |first6=C, |last7=Manandhar |first7=P, |last8=Santiago |first8=M, |last9=Fritzwanker |first9=S, |last10=Schmiedel |first10=F, |last11=Katte |first11=TA, |last12=Reekie |first12=T, |last13=Grimsey |first13=NL, |last14=Kassiou |first14=M, |last15=Kellam |first15=B, |last16=Krasel |first16=C, |last17=Halls |first17=ML, |last18=Connor |first18=M, |last19=Lane |first19=JR, |last20=Schulz |first20=S, |last21=Christie |first21=MJ, |last22=Canals |first22=M |s2cid display-authors =214771721 6 | title = Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. | journal = Science Signaling |date=31 March 2020 |volume = 13 | issue = 625 | pages = eaaz3140 | date = March 2020 | pmid = 32234959 | doi = 10.1126/scisignal.aaz3140 |pmid s2cid =32234959 214771721 | url = https://nottingham-repository.worktribe.com/output/4193457 }}</ref>, rather than functional selectivity or 'G protein bias', asalthough initiallythe reportedvalidity of that conclusion has also been questioned.<ref>{{cite journal | vauthors = Stahl EL, Bohn LM | title = Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists | journal = Biochemistry | volume = 61 | issue = 18 | pages = 1923–1935 | date = September 2022 | pmid = 34468132 | doi = 10.1021/acs.biochem.1c00466 | pmc = 8885792 }}</ref> ''In vivo'', it may have fewer [[adverse effect]]s (including respiratory depression and constipation) compared with [[morphine]].<ref name="pmid24063433">{{cite journal |date vauthors =October 2013Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, Rominger DH, Koblish M, Dewire SM, Crombie AL, Violin JD, Yamashita DS | display-authors = 6 | title = Structure-Activityactivity Relationshipsrelationships and Discoverydiscovery of a G Proteinprotein Biasedbiased μ Opioidopioid Receptorreceptor Ligandligand, [(3-Methoxythiophenmethoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatmenttreatment of Acuteacute Severesevere pain Pain| journal =[[J. Med. Chem.|Journal of Medicinal Chemistry]] | volume = 56 | issue = 20 | pages =8019–31 8019–8031 |doi date =10.1021/jm4010829 October 2013 | pmid = 24063433 |authors doi =Chen XT,10.1021/jm4010829 Pitis}}</ref><ref P,name="pmid24122908">{{cite Liujournal G,| Yuanvauthors C,= GotchevSoergel DDG, CowanSubach CLRA, RomingerSadler DHB, KoblishConnell MJ, DewireMarion SMAS, CrombieCowan ALCL, Violin JD, YamashitaLark DSMW {{Subscription| needed}}}}</ref><refdisplay-authors name="pmid24122908">{{cite journal6 |date=October 2013|title = First clinical experience with TRV130: Pharmacokineticspharmacokinetics and pharmacodynamics in healthy volunteers | journal =[[J Clin Pharmacol|The Journal of Clinical Pharmacology]] | volume = 54 | issue = 3 | pages =351–7 351–357 |doi date =10.1002/jcph.207|pmid=24122908|vauthors=Soergel DG,March Subach2014 RA,| Sadlerpmid B,= Connell24122908 J,| Mariondoi AS,= Cowan10.1002/jcph.207 C,| Violins2cid JD,= Lark25049515 MW}}</ref><ref>{{Cite journal|last=Staff|date=1 October 2015|title=Acute Postoperative Pain|url=|journal=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|type=Paper|volume=35|issue=17|page=40|doi=|pmid=|access-date=}}</ref> In general, ''in vitro'' potency does not guarantee any clinical relevance in humans.<ref name="Waldman">{{cite journal |last1 vauthors = Waldman |first1=SA | title = Does potency predict clinical efficacy? Illustration through an antihistamine model. | journal = Annals of Allergy, Asthma & Immunology |date=July 2002 |volume = 89 | issue = 1 | pages =7-11 7–11; quiz 11-211–2, 77 | date = July 2002 | pmid = 12141724 | doi = 10.1016/S1081-1206(10)61904-7 |pmid=12141724 }}</ref>
 
== History ==
A total of 1,535 participants with moderate to severe acute pain were treated with oliceridine in controlled and open-label trials.<ref name="FDA PR" /> Its safety and efficacy were established by comparing oliceridine to placebo in randomized, controlled studies of participants who had undergone bunion surgery or abdominal surgery.<ref name="FDA PR" /> Participants administered oliceridine reported decreased pain compared to placebo at the approved doses.<ref name="FDA PR" />
 
The U.S. [[Food and Drug Administration]] (FDA) approved oliceridine based on evidence from three clinical trials (Trial 1/NCT02815709, Trial 2/NCT02820324 and Trial 3) of 1558 participants 18 to 89 years old who were in need of pain medication.<ref name="FDA snapshot" /> The trials were conducted at 53 sites in the United States.<ref name="FDA snapshot" />
 
Trial 1 enrolled participants who underwent bunion surgery.<ref name="FDA snapshot" /> Participants with moderate to severe post-surgical pain were randomly assigned to receive oliceridine, placebo or an approved drug to treat pain (morphine) for 48 hours intravenously.<ref name="FDA snapshot" /> Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed.<ref name="FDA snapshot" /> All participants were allowed to use a rescue pain medication, if the pain was not well controlled using the trial medications.<ref name="FDA snapshot" />
 
Trial 2 enrolled participants who underwent surgical removal of abdominal wall fat (abdominoplasty) and had moderate to severe pain.<ref name="FDA snapshot" /> Participants were randomly assigned to receive oliceridine, placebo or an approved drug to treat pain (morphine) for 24 hours intravenously.<ref name="FDA snapshot" /> Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed.<ref name="FDA snapshot" /> All participants were allowed to use a rescue pain medication, if the pain was not well controlled using the trial medications.<ref name="FDA snapshot" />
 
To assess the benefits of oliceridine, participants used a numerical scale to score how severe the pain was after the surgery.<ref name="FDA snapshot" /> The scores for the participants receiving oliceridine were compared to the scores for the participants who received placebo and those who received morphine.<ref name="FDA snapshot" />
 
In the third trial, participants who had pain following various type of surgeries or due to a medical condition received at least one dose of oliceridine.<ref name="FDA snapshot" /> Data from this trial were used only to assess the side effects of oliceridine.<ref name="FDA snapshot" />
 
Oliceridine was approved for medical use in the United States in August 2020.<ref name="FDA PR" /> The FDA granted approval of Olinvyk to Trevena Inc.<ref name="FDA PR" />
 
==Society and culture==
=== Legal status ===
An advisory committee of the U.S. [[Food and Drug Administration]] (FDA) voted against the approval of oliceridine in 2018, due to concerns that the benefit of the drug did not exceed the risk. The risks of oliceridine include prolongation of the [[QT interval]] on the [[ECG]], and [[hypoventilation|depression of the respiratory drive]] (which could cause a person to stop breathing).<ref name="FDA Vote Against 18">{{cite web |title=FDA Panel Votes Against Analgesic Oliceridine |url=https://www.medpagetoday.com/painmanagement/opioids/75668 |website=www.medpagetoday.com |publisher=MedPage Today, LLC |accessdateaccess-date=23 December 2018 |language=en |date=11 October 2018}}</ref> As a result of the committee's vote, the FDA declined to approve oliceridine, citing safety concerns.<ref name="FDA rejection 2018">{{cite web |title=FDA rejects Trevena's painkiller oliceridine {{!}} FierceBiotech |url=https://www.fiercebiotech.com/biotech/fda-rejects-trevena-s-painkiller-oliceridine |website=www.fiercebiotech.com |date=5 November 2018 |publisher=Questex LLC |accessdateaccess-date=23 December 2018 }}</ref><ref name="pmid31010646">{{cite journal | vauthors = Azzam AA, McDonald J, Lambert DG | title = Hot topics in opioid pharmacology: mixed and biased opioids | journal = British Journal of Anaesthesia | volume = 122 | issue = 6 | pages = e136–e145 | date = June 2019 | pmid = 31010646 | doi = 10.1016/j.bja.2019.03.006 | hdl-access = free | s2cid = 128360210 | hdl = 2381/43829 }}</ref>
 
Oliceridine was approved for medical use in the United States in August 2020.<ref name="FDA PR" /> The FDA granted approval of Olinvyk to Trevena Inc.<ref name="FDA PR" />
 
The DEA issued an interim final rule on October 30, 2020, designating oliceridine as CSA Schedule II (DEA Code 9245).{{fcn|date=July 2022}}
==See also==
 
* [[List of investigational analgesics]]
== See also ==
* [[SHR9352]]
* [[Tegileridine]]
* [[TRV734]]
 
== References ==
{{Reflist}}
 
== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/oliceridine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Oliceridine }}
* {{ClinicalTrialsGov|NCT02815709|Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy (APOLLO-1)}}
* {{ClinicalTrialsGov|NCT02820324|Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty}}
 
{{Analgesics}}
Line 145 ⟶ 163:
[[Category:Analgesics]]
[[Category:Biased ligands]]
[[Category:Mu-opioid receptor agonists]]
[[Category:Pyridines2-Pyridyl compounds]]
[[Category:Spiro compounds]]
[[Category:Thiophenes]]
Retrieved from "https://en.wikipedia.org/wiki/Oliceridine"